|
|
Oncogenic MITF dysregulation in clear
cell sarcoma: Defining the MiT family of human cancers
Ian J. Davis1, 2, 4, Jessica
J. Kim1, 2, Fatih Ozsolak1, 2, Hans
R. Widlund1, 2, Orit Rozenblatt-Rosen3,
Scott R. Granter5, Jinyan Du1, 2, Jonathan
A. Fletcher2, 4, 5, Christopher T. Denny6,
Stephen L. Lessnick7, W. Marston Linehan8,
Andrew L. Kung2, 4 and David E. Fisher1,
2, 4,*
1Melanoma
Program in Medical Oncology, Dana-Farber Cancer Institute, Boston,
Massachusetts 02115. 2Department of Pediatric Oncology,
Dana-Farber Cancer Institute, Boston, Massachusetts 02115. 3Department
of Medical Oncology, Dana-Farber Cancer Institute, Boston,
Massachusetts 02115. 4Division of Hematology/Oncology,
Department of Medicine, Children's Hospital Boston, Boston,
Massachusetts 02115. 5Department of Pathology, Brigham and
Women's Hospital, Boston, Massachusetts 02115. 6Department
of Pediatrics, Division of Hematology/Oncology, Gwynne Hazen Cherry
Memorial Labs, University of California, Los Angeles, Los Angeles,
California 90095. 7Huntsman Cancer Institute, University of
Utah, 2000 Circle of Hope, Salt Lake City, Utah 84112. 8Urologic
Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892.
*Corresponding Author, Ph: 617 632 4916; Fax: 617 632 2085.
Received 11 January 2006; revised 7 April 2006; accepted
25 April 2006. Published: June 12, 2006.
|
